1. Home
  2. UNCY vs SBI Comparison

UNCY vs SBI Comparison

Compare UNCY & SBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UNCY
  • SBI
  • Stock Information
  • Founded
  • UNCY 2016
  • SBI 1992
  • Country
  • UNCY United States
  • SBI United States
  • Employees
  • UNCY N/A
  • SBI N/A
  • Industry
  • UNCY Biotechnology: Pharmaceutical Preparations
  • SBI Finance/Investors Services
  • Sector
  • UNCY Health Care
  • SBI Finance
  • Exchange
  • UNCY Nasdaq
  • SBI Nasdaq
  • Market Cap
  • UNCY 91.0M
  • SBI 104.9M
  • IPO Year
  • UNCY 2021
  • SBI N/A
  • Fundamental
  • Price
  • UNCY $6.34
  • SBI $7.47
  • Analyst Decision
  • UNCY Strong Buy
  • SBI
  • Analyst Count
  • UNCY 4
  • SBI 0
  • Target Price
  • UNCY $6.38
  • SBI N/A
  • AVG Volume (30 Days)
  • UNCY 867.0K
  • SBI 39.5K
  • Earning Date
  • UNCY 08-13-2025
  • SBI 01-01-0001
  • Dividend Yield
  • UNCY N/A
  • SBI 4.52%
  • EPS Growth
  • UNCY N/A
  • SBI N/A
  • EPS
  • UNCY N/A
  • SBI N/A
  • Revenue
  • UNCY N/A
  • SBI N/A
  • Revenue This Year
  • UNCY N/A
  • SBI N/A
  • Revenue Next Year
  • UNCY $1,458.53
  • SBI N/A
  • P/E Ratio
  • UNCY N/A
  • SBI N/A
  • Revenue Growth
  • UNCY N/A
  • SBI N/A
  • 52 Week Low
  • UNCY $2.02
  • SBI $6.96
  • 52 Week High
  • UNCY $11.00
  • SBI $8.00
  • Technical
  • Relative Strength Index (RSI)
  • UNCY 48.29
  • SBI 47.02
  • Support Level
  • UNCY $4.70
  • SBI $7.47
  • Resistance Level
  • UNCY $7.58
  • SBI $7.52
  • Average True Range (ATR)
  • UNCY 1.20
  • SBI 0.05
  • MACD
  • UNCY -0.07
  • SBI 0.01
  • Stochastic Oscillator
  • UNCY 26.03
  • SBI 54.55

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.

Share on Social Networks: